Anti-CD19-CD3E-CAR-T cells

PreclinicalCell therapy

SShanghai Changzheng Hospital

Anti-CD19-CD3E-CAR-T cells is one of 39 biologic programs targeting Autoimmune Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Autoimmune DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Blincyto

Amgen

Phase 2

1 5

Cytosar

Teva

Phase 2

1 6

Soliris

Rayos

2 8

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

1 9

Vepesid

AAvyxa

Phase 2

1 10

Bicnu

MMelissa K Accordino

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Recruiting·SShanghai Changzheng Hospital·N/A·NCT06373081·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-CD19-CD3E-CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-CD19-CD3E-CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-CD19-CD3E-CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Changzheng Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: SShanghai Changzheng Hospital

Anti-CD19-CD3E-CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autoimmune Disease1 trial

References

Drug Info

Quick Facts

Related News